Nanotechnology stocks in the United States have held up well in the past two months — unless, that is, they had the misfortune to be associated with silver nanoparticles.
Shares in Nucryst Pharmaceuticals — a company based in Wakefield, Massachusetts, that uses such particles in its popular wound dressings — took another hammering after the US Environmental Protection Agency (EPA) said it would regulate washing machines that used silver nanoparticles to kill germs (see Nature 444, 520; 2006). Nucryst uses such particles in unrelated applications. But its shares — already sharply down after a failed September dermatology trial — took a tumble late last month and are now trading at a quarter of their summer high.
The Lux Research index, which contains a basket of stocks producing and using nanotechnology, has nonetheless held steady. Peter Hebert, chief executive of New York-based Lux Research, which compiles the index, says that despite a weakening US economy, corporate investment in nanotechnology continues to expand. He adds that the EPA ruling has been misinterpreted and won't hurt nanotech as a whole.
The end of the year saw better showings by Flamel Technologies of Lyon, France, whose shares surged after the US Food and Drug Administration approved a GlaxoSmithKline heart drug delivered using Flamel's microparticle system, and have almost doubled to $32 since the summer. And shares in Oregon-based FEI, which makes scanning electron microscopes, rose sharply in November on good quarterly results.
Rights and permissions
About this article
Cite this article
Macilwain, C. Market watch. Nature 444, 805 (2006). https://doi.org/10.1038/444805b
Published:
Issue Date:
DOI: https://doi.org/10.1038/444805b